The PPD clinical research business of Thermo Fisher Scientific has announced the expansion of its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden, that will serve pharmaceutical and biotech customers with advanced laboratory services and leading-edge instrumentation across all phases of pharmaceutical development to help deliver life-changing medicines to patients worldwide.
 
The new 29,000-square-foot laboratory will be adjacent to the Gothenburg strategic research and development site of the global pharmaceutical company AstraZeneca.
 
The PPD clinical research business will expand its bioanalytical capabilities to include comprehensive and full-service solutions, encompassing both small and large molecules, biomarkers and novel modalities. Service offerings will include a wide range of advanced technologies and methodologies, such as cell-based assays, chromatography, flow cytometry, immunochemistry and molecular genomics.
 
“We are thrilled to expand our bioanalytical footprint in Europe – in the collaborative and innovative environment of GoCo Health Innovation City – as we deploy the most technologically advanced systems to develop assays supporting early discovery and subsequently apply them for testing of clinical trial samples across every stage of drug development for our customers,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “Our presence in Sweden will support our customers with accurate and timely data, empowering them to make informed decisions, as we advance Thermo Fisher’s Mission to enable our customers to make the world healthier, cleaner and safer.”
  
The expansion will add up to 140 highly skilled scientists and laboratory support professionals, ranging from entry-level bench positions to general manager. The new lab, which is expected to be completed in the fourth quarter of 2025, will be equipped with state-of-the-art instrumentation, enabling a wide range of GLP-compliant bioanalytical capabilities. This advanced technology will facilitate the delivery of rapid and reliable bioanalytical assay services across all stages of drug development, from preclinical studies to post-approval studies.
 
In addition to the new lab in Sweden, the business operates a global network of GMP (good manufacturing practices), central, bioanalytical and vaccine science laboratories with operations based in Middleton, Wisconsin, Highland Heights, Kentucky, Richmond, Virginia, Athlone, Ireland, Brussels, Belgium, Singapore and Suzhou, China.